Can a simple pill stop a hidden virus after cancer treatment?
NCT ID NCT06575374
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from reactivating in people who have received a type of CAR T-cell therapy called axicabtagene ciloleucel. CMV is a common virus that can cause serious illness when the immune system is weakened. The trial will enroll 36 adults who are CMV-positive and scheduled for this therapy, giving them letermovir by mouth or IV. The main goal is to see if the drug is safe and reduces CMV reactivation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir
What this could lead to
If it works, this could offer a way to prevent a common viral complication in patients receiving CAR T-cell therapy.
What could go wrong
This is a small, early-phase pilot trial with only 36 participants, so results may not apply broadly. Side effects are possible, and the drug may not prevent CMV as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact